++
This chapter will be most useful after having a basic understanding of the material in Chapter 31, Drug Therapy for Hypercholesterolemia and Dyslipidemia in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th Edition. In addition to the material presented here, the 12th Edition contains:
++
Table 31-1 Characteristics of Plasma Lipoproteins which lists the major classes of lipoproteins and their properties
Table 31-2 Apolipoproteins which describes the properties and functions of apolipoproteins that have well-defined roles in plasma protein metabolism
Table 31-6 Assessing 10-Year Risk of CVD Events which provides an algorithm for estimating a patient’s risk of a cardiovascular disease (CVD) event (ie, myocardial infarction [MI], stroke, transient ischemic attack [(TIA)], peripheral vascular disease, heart failure)
Table 31-8 Clinical Identification of the Metabolic Syndrome which provides levels of the five CHD risk factors that define metabolic syndrome
Table 31-9 Guidelines Based on the LDL-C and Total Cholesterol:HDL-C Ratio for Treatment of Low HDL-C Patients which provides an algorithm for treating patients with low high-density lipoprotein cholesterol (HDL-C) levels
Table 31-10 Dose (mg) of Stains Required to Achieve Various Reductions in Low-Density-Lipoprotein Cholesterol From Baseline which provides an algorithm for initiating dosing of statins based on baseline low-density lipoprotein cholesterol (LDL-C) levels
The molecular structures of drugs used to treat dyslipidemias
++
Understand the mechanisms of action of drugs used to treat dyslipidemia.
Know the untoward effects of drugs used to treat dyslipidemias.
Know which patients with dyslipidemias should be treated and when treatment should be initiated.
Know which drugs are most effective in treating patients with different dyslipidemias.
Know which drugs can be used in combination to treat dyslipidemias.
Know the effects of treatment on lowering the 10-year risk of a CVD event, and how to set treatment goals based on primary and secondary prevention of a CVD event.
++
DRUGS INCLUDED IN THIS CHAPTER
Atorvastatin (LIPITOR)
Bezafibrate (not marketed in the United States)
Cholestyramine (QUESTRAN, CHOLYBAR, others)
Ciprofibrate (not marketed in the United States)
Clofibrate (no longer available)
Colesevelam (WELCHOL)
Colestipol (COLESTID, others)
Ezetimibe (ZETIA)
Ezetimibe/simvastatin (VYTORIN)
Fenofibrate (TRICOR, TRIGLIDE)
Fluvastatin (LESCOL)
Gemfibrozil (LOPID)
Lovastatin (MEVACOR)
Niacin (NIACOR, NIASPAN, others)
Pitavastatin (LIVALO)
Pravastatin (PRAVACHOL)
Rosuvastatin (CRESTOR)
Simvastatin (ZOCOR)
++